NICE OKs Xeljanz for individuals with juvenile idiopathic arthritis
Xeljanz is the second drug to be recommended as part of NICE’s new approach to the cost comparison fast track appraisal process
Read More
Tag: juvenile idiopathic arthritis
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
